REBEL EM - December 10, 2020 - By Salim Rezaie
"Clinical Question: Can topically applied timolol maleate ophthalmic solution, 0.5% reduce pain scores at the onset of a migraine better than placebo eyedrops?
Author Conclusion: “This randomized crossover trial supports consideration of timolol eyedrops in the acute treatment of migraine. Further research is warranted to determine if the improvements observed are sustained for a longer follow-up and with larger groups.”
Clinical Take Home Point: Topical 0.5% timolol maleate eyedrops is not ready for primetime in the acute treatment of migraine headaches, but this study is another step forward in potentially adding another medication to the other abortive treatment options available."